Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ViiV Looks Ahead With Third-Gen Integrase Inhibitor From Shionogi

Executive Summary

License deal for preclinical S-365598 continues longstanding R&D relationship between ViiV and stakeholder Shionogi, which also developed dolutegravir and cabotegravir.

You may also be interested in...



Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy

Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.

ViiV Aims To Extend HIV Drug Durations With Halozyme’s Technology

ViiV Healthcare’s head of R&D tells Scrip that extending the durations of its long acting HIV treatments is possible using drug delivery technology from Halozyme Therapeutics to expand the body’s capacity to absorb injected medicines.

Merck & Co./Gilead Team To Take On ViiV In Long-Term HIV Treatment

The companies hope the combination of islatravir and lenacapavir will result in best-in-class oral and injectable long-term HIV products. A PrEP combo is a longer-term goal.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel